Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Entera Bio Ltd.NASDAQ: ENTX
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$3.69M, compared with -$12.35M a year earlier.
Context
- Net debt amounted to 28.1% of total assets at the end of Q1 FY2026, down 29.1 pp from a year earlier.
- Net debt grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +70.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (6.62M) USD
- Year-over-year change
- +21.1%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.62M) | +21.1% |
| FY2024 | 2024-12-31 | (8.39M) | +21.1% |
| FY2023 | 2023-12-31 | (10.63M) | +13.0% |
| FY2022 | 2022-12-31 | (12.22M) | +50.3% |
| FY2021 | 2021-12-31 | (24.59M) | — |
Net Debt vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 net debt of -$3.69M is the 4th highest of the 10 companies compared; the peer median is -$17.58M.
- Its year-over-year change of +70.1% is the 2nd highest of 10, against a peer median of +18.6%.
- Net debt amounts to 28.1% of total assets for ENTX, versus a peer median of 35.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $269.47M | +266.3% | — | 144.5% | |
| Mar 2026 | $50.67M | +65.0% | — | 43.1% | |
| Apr 2026 | -$1.29M | +23.4% | — | 8.7% | |
| Mar 2026 | -$3.69M | +70.1% | — | 28.1% | |
| Mar 2026 | -$5.84M | +3.5% | — | 19.7% | |
| Mar 2026 | -$17.58M | +38.6% | — | 35.3% | |
| Mar 2026 | -$20.64M | -1680.4% | — | 15.4% | |
| Mar 2026 | -$24.29M | +10.2% | — | 8.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$34.03M | +18.6% | — | 50.9% |
| Mar 2026 | -$53.66M | -19.4% | — | 90.9% | |
| Peer median (excluding ENTX) | -$17.58M | +18.6% | — | 35.3% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.